Literature DB >> 1347214

Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration.

S Ponchaut1, F van Hoof, K Veitch.   

Abstract

Liver mitochondria from rats fed 1% (w/w) valproic acid for 75 days displayed an approximate 30% decrease in coupled respiration rates with substrates entering the respiratory chain at complexes I and II. Uncoupling the respiration from proton-pumping, or measuring the respiration without complex IV removed this inhibition. The treatment induced a loss of activity of cytochrome oxidase consistent with a decrease in the mitochondrial content of cytochrome aa3. The inhibition induced by long lasting administration of valproate is apparently located at the site of the proton-pumping activity of complex IV. Furthermore, the capacity of electron transport through complex IV, being far in excess of that required for normal functioning in coupled mitochondria, seems to be controlled by the coupling to proton-pumping in which cytochrome aa3 appears to play a major role.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347214     DOI: 10.1016/0006-2952(92)90590-f

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA.

Authors:  Chih-Ming Lin; Peterus Thajeb
Journal:  Metab Brain Dis       Date:  2007-01-17       Impact factor: 3.584

Review 2.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

4.  Valproate and cytochrome c oxidase deficiency.

Authors:  S Ponchaut; F Van Hoof; K Veitch
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

5.  Glucose metabolism as a target of histone deacetylase inhibitors.

Authors:  Suzanne E Wardell; Olga R Ilkayeva; Heather L Wieman; Daniel E Frigo; Jeffrey C Rathmell; Christopher B Newgard; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2008-12-23

6.  Effect of high-dose vitamins, coenzyme Q and high-fat diet in paediatric patients with mitochondrial diseases.

Authors:  J Panetta; L J Smith; A Boneh
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

7.  Energy metabolism in H460 lung cancer cells: effects of histone deacetylase inhibitors.

Authors:  Nívea Dias Amoêdo; Mariana Figueiredo Rodrigues; Paula Pezzuto; Antonio Galina; Rodrigo Madeiro da Costa; Fábio Ceneviva Lacerda de Almeida; Tatiana El-Bacha; Franklin David Rumjanek
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

8.  Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia.

Authors:  J Skavland; K M Jørgensen; K Hadziavdic; R Hovland; I Jonassen; O Bruserud; B T Gjertsen
Journal:  Blood Cancer J       Date:  2011-02-11       Impact factor: 11.037

9.  Severe hepatopathy and neurological deterioration after start of valproate treatment in a 6-year-old child with mitochondrial tryptophanyl-tRNA synthetase deficiency.

Authors:  Elise Vantroys; Joél Smet; Arnaud V Vanlander; Sarah Vergult; Ruth De Bruyne; Frank Roels; Hedwig Stepman; Herbert Roeyers; Björn Menten; Rudy Van Coster
Journal:  Orphanet J Rare Dis       Date:  2018-05-21       Impact factor: 4.123

10.  Valproate inhibits mitochondrial bioenergetics and increases glycolysis in Saccharomyces cerevisiae.

Authors:  Michael Salsaa; Bianca Pereira; Jenney Liu; Wenxi Yu; Shyamalagauri Jadhav; Maik Hüttemann; Miriam L Greenberg
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.